ClinicalTrials.govpublic full text
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
heart failure with preserved ejection fraction, end stage renal disease on dialysis, end-stage renal disease, sodium-glucose co-transporter 2 inhibitors, heart failure, diastolic function, empagliflozin, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 968905
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.